Conversion Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Retrospective Cohort Study
Open Access
- 26 August 2025
- journal article
- hepatobiliary and-pancreas
- Published by Wiley in Journal of Surgical Oncology
- Vol. 132 (5) , 917-923
Abstract
Background and Objectives: Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant biliary tumor associated with a poor prognosis. Here, we explored conversion therapy (CT) for the treatment of locally advanced iCCA (LA‐iCCA).Methods: We retrospectively enrolled 115 patients with LA‐iCCA at our single center from January 2019 to June 2024, with the final follow‐up conducted in January 2025. The primary outcome measured was overall survival (OS), while the secondary outcome focused on progression‐free survival (PFS). We utilized a propensity score matching (PSM) approach to adjust for potential confounders between the CT group and the systemic therapy (ST) group.Results: Before PSM, the median OS was 34.57 months (95% CI: 19.22–49.91), while the median PFS was 17.30 months (95% CI: 12.89–21.71) in the CT group. Both OS and PFS were significantly longer than those in the ST group (both p < 0.001). After PSM, both groups were successfully matched, resulting in 31 patients in each group. In the CT group, the median OS and PFS were 45.53 months (95% CI: 29.19–61.87) and 18.23 months (95% CI: 7.02–29.45), respectively. Both values were significantly higher than those in the ST group, with P values of less than 0.001 for OS and 0.002 for PFS. Furthermore, CT was identified as an independent factor associated with improved outcomes, both before and after PSM.Conclusions: CT was an effective approach for improving outcomes in patients with LA‐iCCA.Keywords
This publication has 20 references indexed in Scilit:
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trialThe Lancet Gastroenterology & Hepatology, 2022
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract CancerNEJM Evidence, 2022
- Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA RegistryJournal of Hepatology, 2022
- CholangiocarcinomaNature Reviews Disease Primers, 2021
- Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: A systematic reviewCurrent Problems in Cancer, 2021
- Biliary tract cancerThe Lancet, 2021
- Cholangiocarcinoma 2020: the next horizon in mechanisms and managementNature Reviews Gastroenterology & Hepatology, 2020
- Cholangiocarcinoma — evolving concepts and therapeutic strategiesNature Reviews Clinical Oncology, 2017
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010